BIR Annual Congress 2021

4th - 5th November 2021   (GMT+00:00) GMT

Up to 18 CPD credits available

Taking place on Thursday 4 November from 09:15-17:30 and Friday 5 November from 09:30-17:00

If you have registered and not received your joining instructions from Maximillion, please contact them at 

BIR Annual Congress 2021
Working across boundaries for excellence

With a record number of delegates in 2018 and 2019 as well as during the pandemic in 2020, The BIR Annual Congress continues to get even BIGGER and BETTER in 2021!

Due to the uncertainty and keeping in mind the safety of all, we have made the decision to deliver this year's Congress virtually. We are hopeful and looking forward to seeing you all in person in 2022.

A mix of six different streams and seven topics offering a comprehensive programme on the latest innovations in imaging and treatment to medical imaging professionals and their senior management teams.

Taking place over two days, the event provides excellent opportunities to learn, interact and engage with attendees, speakers and industry representatives. There will also be plenty of opportunities to ask questions.


View virtual Congress programme



Day one (Thursday 4 November)

  • Stream A: Musculoskeletal with trauma
  • Stream B: Artificial intelligence
  • Stream C: Therapeutic oncology

Day two (Friday 5 November)

  • Stream A: Management and wellbeing (AM) / Radiation issues for the frontline staff (PM)
  • Stream B: Incidentalomas with incidental findings
  • Stream C: Learning from experts and errors


Key note speakers

  • The Sir Godfrey Hounsfield award lecture by Professor Vicky Goh, King's College London
  • The Canon Mayneord lecture by Professor Clive Kay, King's College Hospital NHS Foundation Trust

Along with these exciting streams, we have interactive sessions with challenging cases followed by Q&A for further engagement.

Who should attend?

Anyone with an interest and passion for radiology, radiation oncology and the underlying sciences, including radiologists, physicists, radiographers, oncologists, physicians, radiation protection advisers and supervisors.

All successful ePosters will be available to view on our Posters and Clips platform by registered delegates only before, during and after the Congress.

Sponsorship opportunities

To secure sponsorship at the congress, please contact us at

Registration fees:
BIR Plan 1 member: £199
BIR Plan 2 / Trainee / International member: £149
BIR Retired / Student member: £99
Non-member: £299

Registration information
Payment for all events must be made via a debit or credit card. Invoices and PO numbers cannot be used for registration payment. If you need your hospital, Trust, or organisation to pay for registration fees, we advise them to fill out the event registration form and return to

If you are having issues registering for the event please create or login to your MyBIR account via this link and then register for the event after you have logged in. If you are still experiencing any issues please email




We are very grateful to the following organisations for supporting this event.

Advanced Accelerator Applications

Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit:


Aidence was founded in November 2015 by Mark-Jan Harte (CEO) and Jeroen van Duffelen (CBO). Based in the Netherlands and the UK, Aidence rallies over 50 data scientists, medical and regulatory professionals, and software engineers to provide intelligent software for the oncology pathway. Aidence’s first clinical application is Veye Lung Nodules, an AI-based solution for pulmonary nodule management on chest CTs. Veye Lung Nodules is currently running in routine practice and lung cancer screening programmes across Europe, analysing thousands of patients scans each week. Aidence has raised €12.5 million to date with top tier VC funds backing.

Annalise ai fuses the highest quality imaging data with the very best in computer science to produce comprehensive AI clinical decision support solutions. The company’s first solution is Annalise CXR, the world’s most comprehensive AI clinical decision support chest X-ray solution on the market. Assisting clinicians to interpret radiological imaging studies, Annalise CXR detects 124 findings, empowering clinicians to make accurate, faster decisions. Our patient-first approach is proudly clinician-led and comes from a deep understanding of the challenges faced in medical imaging. AI provides clinicians with a second set of eyes, allowing them to detect with confidence and drive better health outcomes for all patients.


Bayer’s Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999


BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. The BD Interventional Specialties range is designed to help clinicians deliver better health care. Our primary focus is on improving the patient care experience through reduced procedure times, length and frequency of hospital stays and helping patients in the self-management of their conditions. High standards of clinical training and education are at the heart of what we do and help to ensure that clinicians and patients get the very best from our products.

Everlight Radiology

As the leading global teleradiology provider Everlight helps over 180 UK hospital sites meet growing demand for high quality, responsive radiology reporting. Speak with us on stand to learn more about our unique ‘follow the sun’ global reporting network and international and UK career opportunities.

GE Healthcare Ltd

GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.


NeoDynamics AB (publ) is a Swedish Med Tech Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative precision biopsy system called NeoNavia. The NeoNavia system was developed based on research at the Karolinska Institutet in Sweden where patented “Pulse” technology was found to be beneficial in improving outcomes for biopsy procedures, namely, offering clinicians and patients accurate lesion targeting and high tissue yield, aiding correct diagnosis and individualized treatment. NeoNavia is currently being evaluated at leading clinics in UK as part of the COMPULSE study. We at Neodynamics want to contribute to better diagnostic methods for the millions of women in the world who suffer from breast cancer each year, thereby increasing the chances of survival. Anna Eriksrud, CEO.

Philips Healthcare

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people`s lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people`s health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

Resonance Health

Resonance Health is an Australian healthcare company specialising in the development and delivery of non-invasive medical imaging software and services. Our products are used by clinicians in the diagnosis and management of human diseases and by pharmaceutical companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the management of particular diseases.

Siemens Healthineers

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience, all enabled by digitalising healthcare. An estimated 5 million patients globally everyday benefit from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine, as well as digital health and enterprise services. We are a leading medical technology company with over 170 years of experience and 18,000 patents globally. With more than 48,000 dedicated colleagues in 75 countries, we will continue to innovate and shape the future of healthcare. For more information and latest product line, please visit


TeraRecon is a leader in advanced visualization and artificial intelligence solutions. Our flagship product, Intuition, is the market share leader for radiology and cardiology advanced visualization. Our AI division was awarded the best new radiology vendor for 2018 as well as nominated for best new software in 2019. Further, we were recently named the 2020 & 2021 KLAS Category Leader for Advanced Visualization. We are committed to redefining advanced visualization by leveraging machine learning and improving radiology workflows through personalized automation that increases efficiency.